Abstract 34P
Background
For Ⅱ and Ⅲ stage breast cancers (BCs),neoadjuvant chemotherapy (NCT) is typically the initial treatment.However, there is no evidence to support an improvement in efficacy with dose-dense (DD) chemotherapy (CT) in this setting. Results from clinical trials of neoadjuvant DD-CT in patients with breast cancer are inconsistent.This systematic review evaluates whether DD-CT was more effective than the standard-schedule CT.
Methods
This meta analysis included all comparative prospective and retrospective studies published in Pubmed, Embase, the Cochrane Central Register of Controlled Trials, the Web of Science and the CNKI databases over the past 10 years.The studies that compared the DD-CT with a standard-schedule CT met our inclusion criteria.The primary outcomes were pathologic complete responses (ypT0N0M0: pCR). The secondary outcomes were disease-free survival (DFS) and overall survival (OS). Odds ratios (ORs) for pCR and Risk ratios (RRs) for DFS and OS were estimated and pooled.
Results
Eight studies involving 2477 patients were included in this meta-analysis. Of these, 1214 patients were treated with DD-CT and 1263 patients were treated with CT. The primary outcomes included 8 studies while the secondary outcomes included 7 studies. The pooled rates of the pCR were 19.4% and 11.9% in the experimental and control arms respectively. A significant increase in the pCR [OR= 1.74, 95% confidence interval (CI) 1.38–2.18, P < 0.00001] was noted with DD-CT. Dose-dense treatment also improved DFS[RR= 0.78, 95%CI 0.63–0.98, P = 0.03] and OS [RR= 0.81, 95%CI 0.68–0.96, P = 0.01]. However there was some heterogeneity.Similar results were observed in the further analysis, which was supported by our sensitivity analyses.
Conclusions
The meta-analysis demonstrated that DD-NCT significantly increased the pCR of Ⅱ and Ⅲ stage breast cancer compared with standard-schedule CT. Adjuvant dose-dense regimens can also improve DFS and OS.Taking into account the actual improvement in clinical efficacy,prognostic valueand the acceptable safety profile, DD-CT can be considered a standard approach for neoadjuvant therapy in Ⅱ and Ⅲ stage breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Fourth Hospital of Hebei Medical University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
224P - Associations of pre-existing cardiovascular disease (CVD) with treatment patterns and survival outcomes in patients with localized prostate cancer: A real-world, population-based study
Presenter: Atul Batra
Session: e-Poster Display Session
225P - Prostate cancer treatments and outcomes in the elderly: A retrospective analysis of an Australian real-world cohort
Presenter: Michael Fernando
Session: e-Poster Display Session
226P - Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Andrew Jensen
Session: e-Poster Display Session
227P - Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199
Presenter: Ulka Vaishampayan
Session: e-Poster Display Session
228P - Symptoms and impacts of metastatic castration-resistant prostate cancer (mCRPC) among Japanese patients designated to receive Ra-223
Presenter: Hiroji Uemura
Session: e-Poster Display Session
229P - Expanding the role of supervised exercise on fatigue in prostate cancer patient receiving androgen deprivation therapy: A meta-analysis of randomized controlled trial
Presenter: Niwanda Yogiswara
Session: e-Poster Display Session
230P - Molecular profiling and clinical characteristics of Chinese patients with prostate cancer
Presenter: Ranlu Liu
Session: e-Poster Display Session
231P - Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) 1-3 from KEYNOTE-199
Presenter: Jeffrey Goh
Session: e-Poster Display Session
232P - Real-world data on metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A regional experience
Presenter: Rachel Raju
Session: e-Poster Display Session
243P - Target sequencing of 508 genes in Chinese epithelial ovarian cancer patients
Presenter: Li Lei
Session: e-Poster Display Session